[具有促支气管黏液分泌活性制剂的临床研究：呱西替柳]
[Clinical study of a preparation with bronchomucotropic activity: guacetisal].
作者信息
Rubegni M, De Mauro G
出版信息
Minerva Med. 1981 Feb 28;72(7):429-33.
An open clinical study has been carried out on 40 patients of both sexes suffering from prevalently chronic bronchopneumopathy, with a suspension of guacetisal for adults. The drug is a new bronchomucotropic synthesized by the Bayer Italia S.p.A. Research Laboratories. The improvement in the clinical picture was very evident in 55% of cases and is in favour of an overall positive opinion of the drug's activity bearing in mind that the pathology considered would not in any case have permitted the achievement of complete resolution. The drug was very well tolerated and presented marked mucopoietic and anti-inflammatory properties at a dose of 1 spoonful (10 ml) 2-3 times a day.
对40名患有慢性支气管肺炎的成年男女患者进行了一项关于成人使用呱西替柳悬浮液的开放性临床研究。该药物是由拜耳意大利股份公司研究实验室合成的一种新型支气管黏液促动剂。考虑到所研究的病理情况无论如何都不可能实现完全缓解，55%的病例临床症状有明显改善，这表明对该药物的活性总体持肯定意见。该药物耐受性良好，每日2 - 3次，每次1匙（10毫升）的剂量具有显著的黏液生成和抗炎特性。
Zotero 插件